Significant improvement in cancer management in Europe

Abstract

Abstract Background Cancer management represents one of the most complex disease management segments in health care. Quality National Cancer Control Programmes (NCCPs) play the key role in cancer management in responding to population needs by preventing, detecting and treating cancer only through adequate planning. An effective NCCP represents benefits for patients, citizens, health care providers, health systems and governments. Europe is still characterised by inequalities in cancer control both between and within countries. In response to this challenge, a generic list of evidence-based tools for efficient stewardship and measure of effects of the cancer control will be prepared. Methods A survey on the current state of NCCPs in EU Member States, EEA countries and EU candidate countries and on the presence of some key elements, which NCCPs should include, was conducted in 2018 in the frame of the Joint Action (JA) Innovative Partnership for Action Against Cancer (iPAAC). The completed surveys were analysed; the answers were compared with the report prepared on the basis of the survey carried out in 2011 in the frame of JA EPAAC. Results In total, 33 out of 34 EU Member States, some EEA countries and EU candidate countries completed the survey, the response rate was 97%. Thirty-one out of 33 countries reported that they have a NCCP or another relevant cancer document. Belgium does not have a NCCP, Croatia and Serbia prepared draft versions. The inclusion of patient pathways, quality indicators as well as PROMS in NCCPs is not satisfactory. Only 10 countries included PROMS in their NCCP. Conclusions On the basis of the preliminary results of the survey we conluded that the situation regarding NCCPs in Europe improved in comparison with the situation in 2011. EU countries have mostly adopted a NCCP, plan or strategy as a single or several documents. We aim at developing practical instructions for the successful governance and steering of cancer care in all EU Member States. Key messages The development of NCCPs represents added value for cancer patients in all EU Member States. The inclusion of patient pathways, quality indicators as well as patient reported outcome measures (PROMS) in NCCPs/cancer documents is not satisfactory.